Department of Microbiology and Immunology, University of Miami, Miami, FL 33136, USA.
Cell Transplant. 2010;19(3):253-68. doi: 10.3727/096368909X480314. Epub 2009 Nov 16.
A diversity of immune tolerance mechanisms have evolved to protect normal tissues from immune damage. Immune regulatory cells are critical contributors to peripheral tolerance. These regulatory cells, exemplified by the CD4(+)Foxp3(+) regulatory T (Treg) cells and a recently identified population named myeloid-derived suppressor cells (MDSCs), regulate immune responses and limiting immune-mediated pathology. In a chronic inflammatory setting, such as allograft-directed immunity, there may be a dynamic "cross-talk" between the innate and adaptive immunomodulatory mechanisms for an integrated control of immune damage. CTLA4-B7-based interaction between the two branches may function as a molecular "bridge" to facilitate such "cross-talk." Understanding the interplays among Treg cells, innate suppressors, and pathogenic effector T (Teff) cells will be critical in the future to assist in the development of therapeutic strategies to enhance and synergize physiological immunosuppressive elements in the innate and adaptive immune system. Successful development of localized strategies of regulatory cell therapies could circumvent the requirement for very high number of cells and decrease the risks associated with systemic immunosuppression. To realize the potential of innate and adaptive immune regulators for the still elusive goal of immune tolerance induction, adoptive cell therapies may also need to be coupled with agents enhancing endogenous tolerance mechanisms.
多种免疫耐受机制已经进化出来以保护正常组织免受免疫损伤。免疫调节细胞是外周耐受的重要贡献者。这些调节细胞,以 CD4(+)Foxp3(+)调节性 T (Treg)细胞和最近鉴定的一类称为髓源抑制细胞 (MDSCs)为代表,调节免疫反应并限制免疫介导的病理。在慢性炎症环境中,如同种异体移植免疫,固有和适应性免疫调节机制之间可能存在动态的“串扰”,以实现对免疫损伤的综合控制。CTLA4-B7 之间的相互作用可能作为一种分子“桥梁”,促进这种“串扰”。理解 Treg 细胞、固有抑制细胞和致病性效应 T (Teff)细胞之间的相互作用对于未来辅助开发治疗策略以增强和协同固有和适应性免疫系统中的生理免疫抑制因素至关重要。成功开发调节性细胞治疗的局部策略可以避免对大量细胞的需求,并降低与全身免疫抑制相关的风险。为了实现固有和适应性免疫调节剂在诱导免疫耐受这一仍难以实现的目标上的潜力,过继细胞治疗可能还需要与增强内源性耐受机制的药物联合使用。